Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses key areas of interest in the field of lung cancer treatment, in particular focusing on the KRAS(G12C) inhibitors, AMG 510 and MRTX849. MRTX849 is currently being trialled in combination with doxcetaxel in the KRYSTAL-12 trial (NCT04685135) and AMG 510 is being trialled in combination with doxcetaxel in the CodeBreak 200 trial (NCT04303780). Furthermore, Dr Johnson discusses the increasing number of trials of tyrosine kinase inhibitors targeting HER2 in lung cancer and promising trials involving antibody-drug conjugates. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

свернуть